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Solutions by Patients and Caregivers: The Story of a
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introduction
The Patient Innovation project is an initiative that aims to create a knowledge
commons for patients and nonprofessional caregivers to share and further develop
their innovative solutions to medical care–related problems through an online
platform, https://patient-innovation.com. Patients and nonprofessional caregivers
are the largest, and most important, group of stakeholders in the health care value
chain. After all, the system exists for their benefit. Traditionally, however, they have
been perceived as passive recipients of medical care, merely buying and consuming
the solutions and products that “medical producers” create and provide. This
perspective has influenced the development of an entire health care ecosystem
that reinforces the passive position of patients and caregivers.
The assumption of passivity is highly flawed, as demonstrated by research aimed
at studying innovation activity by “users” in health care and understanding the role
of patients of chronic diseases (or their nonprofessional caregivers) in developing
innovative solutions to help them cope with their health conditions (e.g., Oliveira
et al. 2015; Oliveira and Canha˜o 2016). That collaborative and interdisciplinary
research effort demonstrated that patients and their nonprofessional caregivers are
major sources of health care product and service “user innovations” (e.g., Oliveira
and von Hippel 2011; Oliveira et al. 2015; von Hippel 1988, 2005).
Most of the studies of innovation activity by patients build on several decades of
“user innovation” research. This research demonstrated that ordinary users, not only
commercial entities and research laboratories, are an important source of innovation.
In his seminal work in this area, Eric von Hippel, defined user innovators as firms and
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individuals who innovate to benefit from using their innovation, rather than from
selling it commercially (von Hippel 1988). Translating this definition to the health
care domain, we define patient innovators as those who come up with novel treat-
ments, strategies, and equipment that help them cope with their health disorders or
the disorders of those to whom they give care. For years, failure to appreciate the
potential importance of user innovation led to a lack of attention and support for the
development and diffusion of these innovations, a situation that is only beginning to
be addressed. The assumption of patient passivity may be even more firmly rooted in
the health care context (Oliveira et al. 2015). Moreover, we anticipate that diffusion of
patient and caregiver innovations to others who might benefit from them may pose
particular problems. While patients and caregivers, especially those coping with
chronic or rare diseases, are highly motivated to create solutions for their problems,
for a variety of reasons many do not invest the time and resources that would be
required to share their innovations with other patients. As a result, many valuable
patient-generated ideas may never reach their potential to become solutions and
many valuable patient innovations may disappear without a record.
Our findings of the prevalence of patient innovation (Habicht et al. 2012; Oliveira et
al. 2015) motivated us to seek ways to help patients innovate and share their innovations
more effectively. Eventually, this led us to build an online platform where patients and
caregivers can share their innovations and learn about and suggest improvements to
innovations shared by others. That online platform is the central piece of the Patient
Innovation project. While our rationale for the Patient Innovation platform is fairly
simple, setting up such a platform and governing it are far from simple. It is an ongoing
endeavor, fromwhich we are continually learning. By sharing our experience and some
of what we have learned so far, we hope to encourage others to join our efforts and to
develop their ways of addressing the issues related to patient innovation.
In this chapter, we begin by explaining what patient innovation is and what we know
about it, based on the user innovation and medical literature. We then discuss some of
the challenges that individuals are dealing with as they innovate, andwhy it is important
to help them if we want to obtain their full social benefits. To inform that discussion, we
employ a simple process model of patient innovation. Next, we discuss how platforms
such as the Patient Innovation project can help innovating patients, and describe the
benefits they can provide and themajor obstacles to running them successfully.We end
with a policy-level discussion that we hope will stimulate further action to help taking
patients and caregivers to the front lines of research and development in medical care.
13.1 the importance and potential of patient innovation
13.1.1 Do Patients and Caregivers Innovate?
Studies have documented that, for some diseases, innovations by patients and
caregivers have made a strong impact on medical practice; some even represent
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state-of-the-art technology for the relevant disease (Scherbatiuk 2012). To illustrate
the patient innovation phenomenon, we begin by describing a few well-known
examples of patients and caregivers who have created important medical innova-
tions by building upon their deep intimate knowledge of their health disorders and
the problems associated with them.
Tal Golesworthy, a process engineer, diagnosed with Marfan syndrome in 1992, is
commonly referred to as a man who fixed his heart, for developing an external aortic
root support to prevent its further dilatation (Treasure and Pepper 2015). Marfan
syndrome is a rare inherited disorder that affects the aorta. The term labels the
phenotype of several connective tissue disorders, or “fibrillopathies.” Marfan syn-
drome results in decreasing functionality and resilience of the aorta, and progressive
aortic root enlargement. Golesworthy’s disease progressed to the point where valve
replacement surgery was his only treatment option. Under the standard of care at that
time, after the surgery he would have required a lifetime of anticoagulation therapy.
Golesworthy considered both the surgery and forgoing treatment to be unattractive.
Since he was an engineer, he decided to develop a more suitable solution for himself.
He thought of the issue as a plumbing problem, and, given his engineering expertise,
he believed that he could devise something to keep his aorta functioning without
resorting to valve replacement surgery. He invented the external aortic root support
(ExoVasc), a device designed to fit a patient’s aorta exactly and reinforce it, thus
avoiding both valve replacement and the lifetime anticoagulant drug regimen. In
2004, Tal became the first patient to have an ExoVasc implanted. In 2011, the External
Aortic Root Support Project was the winner in the Medical & Healthcare category of
the Engineer’s Technology and Innovation Awards; in 2015, Golesworthy won one of
the Patient Innovation Awards from our project. By the end of 2015, 56 patients had
received the aortic support ExoVasc (Treasure and Pepper 2015).
Louis Plante, an electronics engineer with cystic fibrosis, developed a low-frequency
waves-radiating device that helps clean mucus from the lungs (Shcherbatiuk 2012).
Removing thickmucus from the lungs is a frequent necessity for cystic fibrosis sufferers.
The standard approach to mucous removal involves a caregiver thumping a patient’s
chest for 20 to 40minutesmultiple times per day. Plante was attending a concert, seated
near a large speaker when he was forced to leave the event because of a fit of coughing.
His expertise in electronics helped him understand that low-frequency vibrations from
the speaker had provoked his coughing (which had the effect of removingmucous from
his lungs). He developed a device that generates similar vibrations without the accom-
panying loud sound. After developing the device for his use, he founded a firm
(Dymedso) to commercialize his solution, thus becoming a user entrepreneur
(Oliveira and Canha˜o 2016). Plante was one of the winners of the 2015 Patient
Innovation Award.
In 2006, The New England Journal of Medicine published an article (Elkins et al.
2006) reporting on the benefits to cystic fibrosis sufferers of hypertonic saline
therapy – inhaling sterilized salt water to clear the lungs of mucus – which has an
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interesting story behind it. Inhaling hypertonic saline was discovered by Australian
surfer and cystic fibrosis patient Emily Haager (Peck 2006). Haager observed that she
felt much better during and after surfing. She traced the effect to her inhalation of
the salty seawater. She disclosed this epiphany to her doctor, who formalized the salt
therapy and reported the results in The New England Journal of Medicine.
To skeptics, these examples may seem exceptional. They also may suggest that, if
they are important, patient innovations will somehow find their way into medical
practice within the existing system. Our research suggests, however, that well-known
examples such as these are only the tip of the iceberg. There is also substantial reason
to believe that important patient and caregiver innovations will fail tomake their way
to wider adoption without systematic efforts to assist their diffusion.
Survey studies in the United States, Japan, Finland, and the UK suggest that
approximately 0.5 percent of citizens have modified or created health-related pro-
ducts or services for personal use (de Jong et al. 2015; von Hippel et al. 2012). In a
study focusing on rare disease patients and their nonprofessional caregivers, whose
needs tend to be underserved by the traditional medical innovation paradigm, we
found a much higher occurrence of patient innovations: 8 percent of 500 survey
respondents had developed innovations that were validated by two medical experts
to be new to medical practice (Oliveira et al. 2015). These studies suggest that there
may be large numbers of patient and caregiver innovators who are responding to
pressing health-related needs by experimenting with new approaches andmodifying
existing solutions.
Of course, not all of these patient innovations are radical or sophisticated.
(Indeed, radical innovation is rare even for well-supported professional researchers.)
Even if it turns out that patient innovations are less likely to be radical than those
made by professional medical researchers, that does not mean that they are insig-
nificant. Good health is not merely the absence of disease or infirmity, but rather an
overall well-being of an individual – physical, mental, and social well-being (WHO
1978). For individuals afflicted with a health disorder, radical treatments or cures
thus are not the only important health care innovations.
The cumulative effect of various solutions that incrementally contribute to well-
being can be extremely important. For those in need, a solution that alleviates the
pressure of a disease or solves a practical problem is well worth having/using, be it
simple or sophisticated.
13.1.2 Why Do Patients and Caregivers Innovate?
User innovation research has identified several factors driving users to innovate. One
of the most important is “sticky information.” Users and manufacturers have differ-
ent types of information that influence the types of innovations they produce. Users
have accurate and detailed information about their day-to-day needs and experi-
ences. As a consequence, they – the users – often tend to develop innovations that are
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functionally novel, which tend to require a great deal of user-generated need
information and context of use information for their development (Riggs and von
Hippel 1994; Ogawa 1998). Commercial entities have detailed information about
the needs of typical or average users, certain types of technical expertise, and
expertise in marketing and diffusing profitable innovations. Synergies between
innovative users and commercial entities are not uncommon, and producers some-
times even pick up user-developed solutions, improve them, and take them to the
market (von Hippel 2010). These synergies tend to be sporadic, however, and the
academic literature in management offers plenty of evidence of under-diffusion of
impactful solutions developed by users (Baldwin et al. 2006; von Hippel et al. 2017).
Patient innovation and innovation by health care professionals may also be
expected to proceed along different, but complementary paths because of the
different information and expertise available to each, which is determined in part
by the way in which the health care system operates. A typical encounter of a health
professional – a medical doctor, for example – with a patient afflicted with a health
disorder is of a short duration. The doctor usually considers an individual’s medical
history, information that the patient communicates about the reasons for the visit,
and various other standard health indicators and bases treatment on that informa-
tion. The doctor’s goal is to identify the problem that brought the patient into the
office and to recommend a solution to remove the problem (cure) or to manage it in
a way that will minimize its impact. The appointment ends, the doctor moves on to
the next case, and the patient is left to cope with any remaining problem(s). Doctors
necessarily must address most of their attention to the most urgent issues confronting
their patients. Nonetheless, problems related to independent functioning on a daily
basis, social integration, and maintaining long-term functionality may have a sig-
nificant impact on quality of life and individual well-being. Moreover, though a
health disorder may manifest itself differently from case to case, and some patients
may have idiosyncratic needs related to the disorder, doctors are unavoidably
limited, in the short time available, in their ability to ferret out and address all but
the most pressing of these idiosyncrasies. Patients also do not seem to believe that
only their doctors appropriately address certain kinds of problems. Survey results
from the Pew Internet & American Life project suggest that patients rely upon
different sources to address different needs: health professionals are more important
for accurate diagnosis, drugs prescriptions, and treatments, while peers, family, and
friends are the dominant sources for finding solutions to cope with their diseases on a
daily basis, and for emotional support – the peer network is especially important for
people with chronic conditions (Fox 2011).
The paths of user innovation and seller innovation also may diverge because users
and sellers have different motivations for innovating. In particular, commercial
firms cannot be expected to invest in innovations that are not expected to produce
significant profits. The mismatch of incentives can be acute in the medical arena.
Consider the situation for those afflicted with one of more than 7000 rare diseases,
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whose sufferers constitute “orphan” markets. This designation means that patients
can expect little help from producers in the form of specialized products to help
them cope with their diseases, as the market incentives are perceived as too low to
motivate vibrant research and development activity from commercial entities.
Because many of these rare diseases are chronic and progressive, and particularly
in light of the lack of commercial incentives, these patients and their caregivers have
particularly strong incentives to develop their solutions – or to discover and adopt
solutions developed by peers – to help them cope with their diseases and improve
their daily lives. Consistent with this observation, our initial studies show an
approximately 10 times higher rate of health related innovation among patients
afflicted with rare diseases and their caregivers than among the public at large
(Zejnilovic et al. 2016).
Our study of 500 patients with rare disease and caregivers provides further
evidence of a correlation between innovative activity and patient/caregiver percep-
tion of need even among rare disease sufferers. The study also suggests, as have
other user innovation studies, that innovative activity increases with level of
education (Oliveira et al. 2015). Moreover, our data suggests that there may be
an important subjective component to the perception of need and that it is an
individual’s subjective perception of need that drives innovative activity.
Additional insight into this possible subjective factor comes from an epidemiolo-
gical study of a representative sample of adult Portuguese (Branco, Rodrigues,
Gouveia et al. 2016). In that survey study, individuals were asked to assess their
general state of health. Some individuals were known to have multiple, clinically
confirmed health disorders; nonetheless, they indicated that their health was very
good, while others, who did not report any significant physical limitations or
illnesses, reported mediocre general health status. While more research is needed
to explore the factors driving patient innovation, it may be that individual percep-
tions of the severity of the need, the likelihood that it will be addressed by others,
and their capability to address it all jointly influence the likelihood that a patient or
caregiver will innovate.
In any event, though many questions about the extent and characteristics of
patient innovation remain, the available evidence leads us to believe that a sub-
stantial amount of patient and caregiver innovation occurs. Unfortunately, there is
also reason to believe that only a small fraction of patent innovations are ever shared
with other patients and caregivers, adopted by physicians, or picked up by commer-
cial providers. Given the fact that, globally, many individuals are innovating to cope
with their health disorders, we believe it is important to consider how best to support
patient innovation so that it will be as effective, safe, and socially beneficial as
possible.
In the next two sections, we discuss the challenges and opportunities of patient
innovation, from individual-level and platform-level perspectives and how the
Patient Innovation project seeks to support it.
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13.1.3 An Individual-Level Model of Patient Innovation
To gain a better understanding of the innovation activity of patients and caregivers
and identify ways to improve it, we model it with the Patient Innovation value chain
shown in Figure 13.1. The underlying goal of this value chain is that the drivers of
patient innovation will lead to the development of new treatments, therapies, and
medical devices, which should be validated for safety and efficacy, and then diffused
more broadly. Ideally, the economic and social impact of the output of the value
chain should then bemeasured and evaluated. The integration of patient innovation
into health care innovation represents a paradigm shift. While this shift is already
happening, no studies yet assess its economic and social impact.
The Patient Innovation value chain starts with an identified need – a driver of
patient innovation – that prompts the innovation itself. The process of patient
innovation is easy to imagine, but it does not proceed according to the kind of
structured process often implemented by commercial firms. The process of user
innovation is likely to be an unstructured, iterative decision-making sequence, similar
to the model proposed by Mintzberg et al. (1976), involving experiential learning,
serendipitous jumps over the stages, and events that originate from the environment in
which the users are embedded and which influence the process. Nonetheless, when
considering how best to intervene in the Patient Innovation value chain, it will be
helpful to devise an easy to interpret process model to help guide our interventions.
To develop our model, we conducted a qualitative study in Portugal, by interview-
ing 15 patients afflicted with chronic diseases or lesions (Oliveira 2014). From these 15
interviews, we identified 30 cases of patient innovation, adoption, or passive behavior
by patients. Our analysis, grounded in the existing literature on user innovation and
individual decision making, yielded a simple stylized develop-or-adopt process model
of patient innovation (Figure 13.2). In Figure 13.2 we also show, in parallel, how this
model compares to two other representations of the innovation process, the stages of
development of a user innovation (Lu¨thje et al. 2005), and a decision-making model –
the trichotomy identification-development-selection model (Mintzberg et al. 1976).
In this representation, the patient’s problem-solving activity is a dynamic, iterative
process that ends in either adoption or innovation. The linear representation of the
stages is not meant to imply that every problem-solving activity by patients passes
through all the steps in the order shown, as problem-solving is inherently an
unstructured process embedded in a dynamic stochastic environment (Cooper
2008; Langley et al. 1995). Sometimes, for example, a patient may simply develop
a solution, without any search. This simple model nonetheless provides a useful
Drivers of patient
innovation
A paradigm shift:
Innovations by
patients
Safety and
efficacy
validation
Diffusion: the
role of social
networks
Measuring
economic and
social impact
figure 13. 1 The Patient Innovation value chain.
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structure within which potential interventions – aimed at helping patients make
better decisions and obtain better outcomes from their innovation activity – may be
considered. We will use this model to also describe our intervention, the Patient
Innovation platform. However, before we move to the platform-related discussion,
let us briefly describe the phases of the model, supporting them with selected
interview excerpts.
13.1.3.1 Stage 0: Unmet need
As any problem-solving process starts with the identification of unmet need, this is
the initial stage of the patient innovation develop-or-adopt process. There are two
ways for individuals to become aware of a need: (1) through experiential learning – a
form of learning-by-doing/using where a patient observes an unmet need and then
attempts to formulate the problem informally (vonHippel 2005) or (2) by observing a
solution simultaneously with identifying a need (vonHippel and von Krogh 2013). In
8 out of the 30 cases we analyzed, upon observing a problem, the patients immedi-
ately came up with a solution and pursued its development. A need may also be
recognized by observing a solution (von Hippel and von Krogh 2015), and this was
the case in 3 out of the 30 cases we analyzed; patients saw a solution and then
realized that the solution was a match for a latent need or for a problem they had
attempted to solve in the past:
0)
UNMET
NEED
1)
SEARCH
(for solutions:
adopt-or-
develop?)
2 a)
DEVELOP
2 b)
ADOPT
3)
USE
(goodness 
of fit
assessment)
4 a)
No diffusion
4 b)
SHARE
(peer-to-peer)
4 c)
COMMERCIALIZE
Idea Specification Prototyping Diffusion
UI activity phases (Lüthje et al. 2005)
Decision making phases (Mintzberg et al. 1976)
Development
Selection
Identification
figure 13.2 A stylized model of a patient’s adopt-or-develop process with
corresponding phases of user innovation activity and decision-making processes. The
arrows indicate potential paths of problem solving – the transitions from one stage to
another (UI - User Innovation).
308 Pedro Oliveira, Leid Zejnilović, and Helena Canha˜o
available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781316544587.014
Downloaded from https://www.cambridge.org/core. ITQB Library, on 17 Apr 2019 at 17:35:03, subject to the Cambridge Core terms of use,
As I was watching TV, I saw a university professor talking about a software he
developed to control computers with eye movements. He developed the software
to help his wife in her work with people afflicted with cerebral paralysis. The
software was free to use, and I thought about my difficulties to use computers. So, I
gave it a try.
(Tetraplegia, patient – interview D)
In this example, the patient was aware of difficulties when using a solution, but the
need was latent as he was not actively pursuing or searching for a solution. Hearing
about the software, the patient’s latent need got activated and by adopting the solution,
his quality of life has been improved.One takeaway from this example is that increasing
the availability and salience of solutions may help people in unanticipated ways.
13.1.3.2 Stage 1: Search for information and solutions
If a solution does not immediately present itself upon recognition of unmet need, the
next step is often to undertake a search for information and solutions. Real-life
decisions are complex, and in response to a problem, people often do not search for
the best possible solution, but for one that satisfices – fixes the problem to an extent
that is satisfactory for their needs (Simon 1977). Descriptivemodels of decisionmaking
include a search for solution alternatives as part of a development phase. In decision-
making procedures, the relevant subroutine or procedure (Mintzberg et al. 1976)
employs an algorithm to develop alternatives that are subjected to a cost-benefit
analysis against the previous best solution (Newell and Simon 1972). Having identified
an unmet need, patient innovatorsmay engage in a similar, though usually less formal,
search process. The dynamics of the search for health-related information change as
patients and caregivers gain experience about the health condition of interest:
When she was diagnosed, I sought for support and information about epidermolysis
bullosa. However, it is a rare disease, and with so few patients like her, it was difficult
to find help. I searched everywhere, online fora, international associations, journals,
pharmaceutical companies. I do it nowadays as well, but more to learn about a
specific thing or to find new solutions. [Apart from innovating] I also adopted a
solution developed by another patient, and I found it on an international online
forum – to add table salt to bathing water, as skin contact with pH neutral or isotonic
solution lessens the sting. I also experimented with sea salt instead of table salt, and it
works even better for my daughter.
(Epidermolysis bullosa, caregiver – interview F)
In the beginning, I would search a lot for information about my condition, whereas
nowadays I only search for specific information or solutions, when I feel it is needed.
Usually, I search online (e.g., YouTube or scientific papers), but also, I ask other
patients with spinal cord injuries and doctors.
(Spinal cord injury – patient – interview I)
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In the early stages, when an ailment is contracted, patients and caregivers search
mostly for information about the nature of their ailment and the prospects of living
with it. As they accumulate knowledge about their health condition and learn how to
function with it on a daily basis, patients tend to engage more intensively in
searching for specific solutions to their unmet needs.
It was obvious from our interviews that there is a stark contrast between active and
passive patients. Active patients detailed about search behavior, solution development,
tinkering, and adoption. Passive patients demonstrated strongly reliance on doctors only:
I do not search for health-related information. All that I need, I get from health
professionals in the rehabilitation center.
(Spinal cord injury, patient – interview L)
We also asked the interviewees for their opinions about solutions that patients develop
for themselves. We wondered whether patients’ lack of confidence in their expertise
would lead them to eschew solutions developed by other patients. The non-active
patients we interviewed (such as the one from interview L) were not opposed – in
principle – to the idea of adopting a solution developed by a patient. Rather, they
expressed no need for such solutions, finding their existing medical care sufficient.
Not all patients who identify an unmet need begin their searches for solutions. In
what is referred to as the “community push,” patients may instead share the problem
with others, who may then suggest solutions they know about or are using. We
identified two such cases, which we elaborate upon in our discussion of the diffusion
phase, since responding to inquiries from other patients is one mechanism for
diffusing innovations.
13.1.3.3 Stages 2 and 3: Develop-or-adopt and then use a solution, an iterative
trial-and-error process
The stage 1 search for a potentially satisfactory solution ends with a decision to adopt or
develop a possible solution. This initiates a solution development (stage 2a), or acquisi-
tion of an existing solution (stage 2b). After obtaining the firsthand experience using the
solution (stage 3), or even during the solution acquisition, the goodness-of-fit of the
solution to the need is assessed (stage 3) based on the patient’s personal cost-benefit
assessment (e.g., Damanpour 1991; Rogers 2003). There is no guarantee that the out-
come will be a satisfactory need-solution pair. In cases of mismatch, the patient may
return to stage 2a for further development or to stage 1 for further search. Searching for a
match is often a dynamic, iterative, trial-and-error process, both for solutions developed
independently by the patient innovator or adopted from preexisting technology:
Every time we encounter a new problem, we start by searching online to see if there
is a solution, and we consider if we can come up with something by ourselves.
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. . . we were desperately trying to find a solution . . . something that would help
KK to hold the dish when he places a spoon or a fork in it, or . . . in whatever he is
eating. We searched everywhere and tried several things. For example, we tried
available silicone adherent mats, but they were too big and did not hold well.
However, once, when we bought a big bowl in a shop, I realized that it had a small
silicone adherent mat inside, to hold the bowl, and it came tomymind that I should
give it a try with KK . . .we used it and it worked so well for him. It holds whatever he
is eating, he can eat by himself, and it is small, so he is OK to use it at school too (it is
discrete). He now uses it for every meal.
(Hemiparesis, caregiver – interview K)
The guys in Brazil shared everything with me for free, about their surfboard, the
chair attached to it, and how to make it. However, making it was a lengthy and costly
process. It was even more difficult as their solution was custom made, and I decided
that it was better to make a general purpose solution, something that anyone can use.
(Poliomyelitis, patient – interview C)
If patients are not satisfied with the cost-benefit performance of potential solutions,
they can conduct a new stage 1 search or return to stage 2 to refine or modify the
solutions they have developed or adopted. In 8 of the 30 cases we analyzed, patients
returned to stage 1 search after being dissatisfied with a potential solution, while in 11
out of 30 cases patients engaged in iterative refining or modifying the adopted or
developed solutions. Patients, who initially attempted to solve their problems by
adopting an available solution (stage 2b) uncovered during their search, may recog-
nize the need to develop their innovative solution (shifting to stage 2a). This usually
happens after a trial use of a recommended available solution, finding it to be
inadequate:
They [the doctors] gave us the orthopedic cast for my son’s functional arm, but it
was heavy, not practical, and did not quite do what we expected . . . I realized that
I could just sew the sleeves on the functional arm, and that worked much better.
(Hemiparesis, caregiver – interview K)
Rosenberg (1982) describes the trial-and-error process that we represent as iteration
among stages 1, 2, and 3 as “learning-by-using.” The accumulation of use experiences
creates tacit knowledge, or what von Hippel (1994) refers to as sticky information.
The cases we encountered show that users, based on their sticky information, may
come up with more effective solutions than their commercial counterparts
(Morrison et al. 2000; von Hippel 2010).
13.1.3.4 Stage 4: Diffusion of patient-developed solutions
Most patient innovations are potentially valuable to other, similarly situated patients
and caregivers. Thus, the full social value of innovation is obtained only if it is shared
with and used by other patients. Making solutions publicly available allows others to
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find solutions to problems they are attempting to solve (contributing to stage 1) and
for need-solution pairs to arise (contributing to stage 0). In 13 out of the 22 cases that
involved a developed or adopted solution, the patients made efforts to diffuse further
the solutions. In diffusion efforts, solution developers may share information in a
relatively passive way, such as by making an online post or preparing other types of
written information. They can also actively suggest the use of a solution, a “market-
push” approach, in which they bring the solution to the attention of people with
whom they interact. We identified two such market-push cases. In such cases, we
found that those who suggested a potential solution to a particular individual also
provided help to reduce the solution’s acquisition cost. The diffusion channel in these
examples was a two-way interaction between peers, suggesting that social interactions
with peers may increase the likelihood of adoption of patient-developed solutions.
At times, particularly when there is uncertainty about the safety and effectiveness
of a potential solution, the patients may also involve medical doctors in the innova-
tion process:
We (the parents) exchange information about drugs, and the experiences with different
combinations of drugs, what worked and for what. We experiment with different
combinations of drugs to see which one works better. I did it at least once for my kid.
First, I informed myself about a combination of drugs that other parents suggested.
Then I went to my doctor and explained what I found, the reasons why I need it, and
the doctor was enthusiastic and supportive about it. Therefore, I tried it, and it worked.
(Child with Angelman syndrome, caregiver – interview E)
This example demonstrates the importance of the doctor-patient relationship.
Namely, hazardous solutions can be identified with higher confidence if they are
openly discussed with experienced professionals, and not solely within the commu-
nity of patients.
Although most of the innovators in our sample made some efforts to share their
solutions – after all, this is how we found them – in 2 out of 13 cases of developed
solutions, the developers did not share their solutions, even though they were well
connected to other patients and medical professionals. The patient innovators reported
either that they had no time to engage in diffusion or simply that they did not share their
solutions because no one asked. These observations are in line with the general
arguments about potential market failure in the diffusion of user innovations presented
by de Jong et al. (2015). It was very rational for some innovators not to share information
about their solutions with others – after solving their problems they had no interest in
investing time or money in diffusing the solutions. Where diffusion of a valuable
solution does not occur, another patient or caregiver looking for a solution to a similar
problem must replicate the whole development process. That replication is a waste of
resources, and the patients may or may not succeed in finding or developing a solution.
The cases of non-diffusion that we analyzed demonstrate that failure to diffuse may
occur even when developers would be willing to share them for free – when patient
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innovators find sharing too burdensome or are unaware that others might be interested
in knowing about them. The cases thus suggest that actively soliciting solutions from
patients and educating them about the value of sharing the outcomes of their creative
activity, as well as creating the infrastructure to reduce the costs of sharing, may be
important to correct this market failure.
The model presented here provides an overview of the patient innovation process
from the perspective of the individual innovator. In our design, implementation,
and ongoing efforts to improve the Patient Innovation platform, we use this model to
help us identify ways to move forward – in other words, to learn how an online
platform can be used to address some of the challenges patients encounter in the
process and to contribute to the development of patient innovation on a larger scale.
13.2 the patient innovation online platform:
infrastructure for a knowledge commons
Next, we discuss how the Patient Innovation platform can help overcome some of
the barriers to successful patient innovation and diffusion of those innovations by
providing the infrastructure for a knowledge commons.
13.2.1 The Landscape of Health Care–Related Online Platforms
Health care systems are under serious pressure to deliver good medical care despite
capacity and budget constraints. Total spending on health accounted for 9.5 percent
of GDP in the Organisation for Economic Co-operation and Development coun-
tries in 2012, and the cost is still rapidly rising, particularly because the population is
aging and, relatedly, because more people are living longer with chronic diseases.
Chronic diseases are the most common cause of death globally, accounting for 75
percent of direct health care costs in the United States, and taking a significant toll
on the quality of life of the elderly (Thrall 2005; Vos et al. 2013). There is a common
understanding that novel solutions and business models are necessary to help over-
come constraints, contain costs, and unlock new opportunities. Technology, and
especially digital platform-based business models, may be an important contributor
to better and more cost-effective health care.
In the Merriam-Webster dictionary, a platform is defined as “a place or opportu-
nity for communicating ideas and information.” A “digital platform” is a set of
components including a core, upon which third parties can build (Parker and Van
Alstyne 2010). The value of a digital platform is characterized by network effects,
meaning that it becomes more valuable when more third parties use and contribute
to it. Popular examples of digital platforms include hardware and software environ-
ments such as Google Play Store, as well as websites where sellers and buyers are
matched, such as Amazon, eBay, or Uber, which matches available amateur taxi
drivers with people who need a ride. The Internet itself is a platform – an
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infrastructural platform. It enables the development of efficient, sustainable online
resources that individuals can use to create and exchange knowledge, research
pressing questions, communicate with one another, and even act upon their ideas.
In the health care arena, patients have been empowered by the resources available
on the Internet to assume more responsibility for their medical care. Greater
involvement of patients in managing their health may also decrease the burden on
the health care system (Hibbard et al. 2004). In recent years, patient organizations,
providers, commercial entities, and nonprofit organizations have developed a variety
of online communities and virtual fora where patients can not only discuss their
health concerns but also capture, record, and exchange valuable health-related
information. In a similar vein, the US Food and Drug Administration made an
additional effort to bring closer to patients their existing platform for reporting
adverse effects of medical devices and drugs, MedWatch (FDA 2013). It introduced
an easy-to-understand report form that can be downloaded fromMedWatch website,
and a way to submit the report online, aiming at consumers with little medical
knowledge. Other interesting examples of online fora include the Braintalk com-
munity for neurological diseases and Building User Involvement in Motor Neuron
Disease (BUILD) for amyotrophic lateral sclerosis (ALS). Going beyond commu-
nication and knowledge exchange, pharmaceutical companies are also keen to
organize virtual clinical trials, in which the data collected is self-reported by patients
(Roehr 2011).
Major technology companies, such as Apple, Google, IBM, Microsoft, and
Samsung, also have stepped in to offer health care–related initiatives. Their strate-
gies include open source frameworks for creating health-related software applica-
tions, providing medical data storage and analysis, and processing large amounts of
health-related scientific data. Connecting users to report and share health data is
also a business model for platform-based companies, which are harnessing the
increasing availability of Internet connectivity to assist patients in finding and
interacting with other people suffering from similar conditions. For example,
PatientsLikeMe is a for-profit health data-sharing platform that aggregates patient-
contributed health data to perform observational studies. PatientsLikeMe has more
than 150,000 active users sharing data on more than 1000 health disorders. A study
performed using this platform disproved a previous scientific paper regarding the
effects of lithium carbonate in amyotrophic lateral sclerosis (ALS), by systematically
collecting and analyzing self-experimentation information provided by patients
(Wicks et al. 2011). Genomera, another online project, is “crowd-sourcing health
discovery by helping anyone create group health studies” (Genomera 2013). These
new platforms seek to enable patients, caregivers, and others whose input to medical
research previously has been limited to a passive role. They create and enable
communities that can help in coming up with suitable designs for testing hypotheses
or answering questions by connecting knowledge but also locating peers willing to
serve as testers, implementing the test design and sharing their symptoms and
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outcomes. These existing efforts demonstrate the potential for the Internet and
related technology to enable the engagement of patients and patient associations,
nonprofessional caregivers, health professionals, and even medical doctors who
have, so far, been considerably excluded from the health innovation process.
13.2.2 The Patient Innovation Platform
The Patient Innovation initiative differs from prior online health platforms in that it
aims to recognize and enhance the capacity of users – patients, caregivers, and
collaborators with complementary skills who are intrinsically motivated to help
people in need – to contribute to innovation in medical care. To that end, we
developed and deployed the Patient Innovation platform, https://patient-innovation.
com, a non-profit digital platform designed to provide infrastructure to support a
knowledge commons for identifying, sharing, commenting on, improving, and
diffusing the work of thesemedical user innovators. The Patient Innovation platform
is international, multilingual, open, and free for use by patients and caregivers
dealing with any disease. The platform was launched in February 2014 and relies
on partnerships with numerous patient associations and medical research centers in
the five continents to reach international audiences.
To increase public awareness of the potential benefits of patient innovation, we
established the Patient Innovation Award. Each year we invite patient innovators to
submit their best innovations to the competition. A jury composed of six highly
reputable scientists reviews the proposed solutions and selects the innovator of the
year in three categories – patient, caregiver, and collaborator. The awards are
presented at a ceremony, which provides an opportunity to raise awareness of the
Patient Innovation project. At the same time, this is an excellent occasion to gather
individual patients, patient associations, health professionals, innovation experts,
entrepreneurs, media, companies, and health authorities to discuss patient and
caregiver innovation.
The Patient Innovation platform design invites patients and caregivers to submit
their self-developed solutions as video files, sets of pictures, textual narratives, or a
combination of thesemedia. Other members of the network are free to evaluate each
proposed solution, make their judgments about its applicability, safety, and to which
problems it could usefully be applied. Also, members may engage in a co-creation
process and upload modified versions of others’ solutions, so that the path of
development can be traced by users of the site. Tagging mechanisms and advanced
search capability allow efficient search by patients and interested parties and may
enable cross-pollinating of solutions across health disorders. The platform has the
potential to become a unique repository of open knowledge, created and co-devel-
oped in a patient-to-patient trusted environment, about innovations to enhance the
health and quality of life of chronic disease patients.
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The Patient Innovation platform is intended to enable patients to assume more
responsibility for the collaborative development and diffusion of their innovations,
and to allow patients to contribute more knowledgeably to medical care. To further
that goal, we designed the Patient Innovation platform to mesh strategically with the
stages of patient innovation mapped out in the process model presented in Figure
13.2. The relationships between the design of the Patient Innovation platform and
the stage of innovation activity are summarized in Table 13.1.
We see Patient Innovation and similar initiatives as useful efforts to bring health
care closer to the patients, to enhance the participation of patients in the manage-
ment of their health, to incorporate the patients’ and caregivers’ valuable use-based
knowledge into the improvement of medical care, and to provide conduits for
practical learning about how to improve struggling health care systems on a global
scale. Because such initiatives involve humans and their well-being, they are
embedded in complex legal, regulatory, and social environments. In such a land-
scape, new approaches to medical innovation may be in some tension with existing
legal and social norms. We believe that such tensions, where they arise, should not
discourage us from seeking means to incorporate patients and caregivers into the
medical innovation ecosystem. Rather, they highlight the need to adapt health care
systems and public policies to provide a meaningful framework for integrating
patients and caregivers (and their important use-based local knowledge) more
fully in the development of safe and effective health care solutions.
13.2.3 Challenges and opportunities in developing the Patient
Innovation platform
We encountered (and continue to encounter) many challenges in designing and
maintaining the Patient Innovation platform. Here, we discuss a few of the most
significant challenges, and our response to overcome them. The most basic chal-
lenge for any digital-platform business is the creation of a community of users. The
community supplies the content, without which the platform has no value. In the
case of the Patient Innovation platform, the content consists of information about
health-related patient innovations and the record of improvements to these solutions
made by other patients. The community also plays the role as the demand side of the
Patient Innovation platform. Those with health disorders may use the platform to
learn about potential solutions to their needs by browsing descriptions of existing
solutions developed by their peers. As they browse, community members can
provide new content, feedback, and validation of usefulness (or not) of the posted
solutions. As more community members participate as content providers or users of
the content provided by a platform, the community becomes stronger, and the
platform that supports the community becomes more valuable.
We engaged in developing the Patient Innovation platform in the face of sub-
stantial evidence that users – and in this case, the patients, caregivers, and
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table 13.1 Stages of innovation activity by patients and the associated challenges and opportunities for the Patient Innovation platform
Stage The function provided by patient innovation
The expected improvements in the patient innova-
tion process
UNMET NEED
Need identification
Solution tagging and search by tags: disease, symptom,
location, and activity tags
Faster identification of potential problems/solution
SEARCH
Search for solutions
Faster and more successful search for a solution
Spillover of knowledge from different diseases/solution
categories; e.g., solutions for digestive problems as a
primaryhealthdisorder can serve to thosewhohave it
as a side effect of a cancer treatment
ADOPT
Adoption
Safeguard mechanism for obviously dangerous solutions
Descriptions of the solutions: textual, audio, and visual
Social networking feature: commenting
More solutions/versions to choose from
Low investment in the acquisition of a solution
DEVELOP
Development
Comparison with the existing solutions, and
incremental buildups
USE
Goodness-of-fit assessment
Reviewing and updating use-related information
/experiences from the users
Collection of evidence about solutions
DIFFUSE
Sharing and/or commercializing
Free-of-charge and easy to use/post solutions platform
Promotion
Higher rate of diffusion of patient-developed
solutions
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collaborators – often do not have strong enough incentives to share their content,
given the time, effort, and resources that sharing requires. By creating a specialized
venue for sharing peer-developed solutions, Patient Innovation lowers the barriers to
diffusing patient innovations. An equally important role of the platform is to increase
awareness about the potential importance of the patient innovation phenomenon,
thereby bolstering patient innovators’ intrinsic motivations to help others by sharing
their innovations. During Patient Innovation’s three years of operation so far, more
than 700 solutions have been posted on the platform.
When we began developing the Patient Innovation platform, we had to make
decisions about the governance of the platform. We desired to maintain as much
openness as possible in light of our overall goals. We also hoped to create a
sustainable knowledge commons based on the platform. Sustainability is dependent
on maintaining a vibrant community and also on the mechanisms for funding and
supporting the platform itself. We believed that sustainability would be enhanced by
aligning the intended identity of the community with the mechanisms used to fund
its development and maintenance The goal of sustainability thus had implications
for our decisions about the platform provider, its legal structure, and the platform
sponsors. We believed that a commons based on our fundamental commitment to
openness and free peer-to-peer sharing would only be viable in an environment of
trust. To encourage a trusting environment, we decided to structure Patient
Innovation as a not-for-profit organization and to fund platform development and
maintenance only through research grants and donations. Maintaining trust also
requires that we keep the commons governance free of conflicts of interest, by
working only with partners who share the same values and are dedicated to and
invest efforts in better empowering patients within the health care system.
We also confronted decisions about the type and degree of openness to employ in
governing the Patient Innovation platform. The openness of a platform (and the
knowledge commons it supports) is multidimensional. For Patient Innovation,
decisions had to be made about who could contribute content, what types of content
could be contributed, and which contributed content would be displayed. (It went
without saying that the content of the platform would be available for anyone to
explore and use.) In line with our primary goal of promoting better medical care, we
imposed some limitations along various dimensions of openness.
Patient Innovation is completely open about who can contribute, but we had to
decide whether to allow anonymous participation or to employ some means of
authenticating the identities of those who post on the site. There are benefits and
weaknesses to authenticating participants in a virtual community versus allowing
anonymous participation, including questions about the quality and value of anon-
ymous peer-review feedback mechanisms. Trust among those who create and use
the content of the knowledge commons supported by the Patient Innovation plat-
form is also important for sustainability. Inappropriate or otherwise deleterious posts
could easily erode this trust. User authentication is one means of discouraging
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disruptive (and, in this case, potentially dangerous) contributor behavior and incen-
tivizing higher-quality participation. However, we did not want to discourage
patients from participating, even if they preferred to remain anonymous. We thus
decided to permit anonymous contributions, while incorporating other mechanisms
of quality assurance to address our concerns about sustainability, trust, and safety.
We address the issue of quality assurance primarily by imposing some limits on
what types of content can be posted and which particular contributed content is
displayed. Like many other online communities, we employ community ratings and
feedback to identify disruptive or otherwise inappropriate contributions. The med-
ical context raises additional quality control concerns, and specifically related to
safety, that we feared might not be adequately addressed by relying only on com-
munity feedback. We employ two additional mechanisms to alleviate these con-
cerns. First, because of the particular difficulty in assessing the safety and efficacy of
drugs and other ingestible treatments, Patient Innovation’s terms of service simply
forbid the posting of solutions involving drugs or other ingestible products. Second,
each post is reviewed by a medical professional before it becomes visible on the site.
This review ensures that contributions comply with the terms of service and satisfy
the basic requirements of safety. The involvement of medical professionals in
reviewing posts serves the additional purpose of beginning to bridge the gap between
patient innovation and the medical professions. Bridging this gap is a worthwhile
goal, given the important role that medical professionals play in validating and
diffusing medical innovations.
Another dimension of openness relates to the potential uses of the content
available on the site. One way to enhance the value of the content pooled in a
knowledge commons is to permit third parties to design tools that interface with that
content. A pertinent example of such a tool might be an application that allows users
to report their health indicators before and after using a specific solution posted on
the platform. Patient Innovation is open so that third parties can create tools that
interface with the platform to enable collection and sharing of evidence about the
effectiveness of the solutions. Our decision to make the platform open along this
dimension was guided by our commitment to advancing paradigm change in health
care in the direction of distributed innovation and patient-centric medical care.
Validating the safety and efficacy of patient innovations remains a major chal-
lenge, and we continue to consider ways in which a platform such as Patient
Innovation might contribute to that task. The usual path for bringing medical
innovations to the market requires clinical trials, defined as sets of tests that generate
data on the safety and efficacy of health interventions. The merits of the clinical trial
procedure are undoubted, but traditional clinical trials have serious drawbacks as
well (e.g., Appel 2006). One major issue is the delay in patient access to newly
developed treatments caused by regulatory constraints and clinical trial practices.
Another related concern stems from the fact that safety and efficacy questions are
most easily answered when a disease is common, and the outcome of interest has a
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high chance of occurring. In the case of rare diseases, the challenges are great, as
trials of sufficient size are often impossible because of the difficulty of recruiting a
sufficiently large sample of patients with a rare disease of interest (Hayes 2012).
This discussion suggests a need for developing new methods and more pragmatic
practices for validating the safety and efficacy of at least some types of medical
innovations, including (1) treatments, therapies, or medical devices developed by
patients, who lack incentives to diffuse their innovations and do not have access to
the resources needed to perform standard clinical trials and whose innovations may
be tailored to circumstances encountered by relatively small numbers of patients
and (2) innovations aimed at rare diseases, for which it is very hard to apply common
methods of clinical trials for uncommon medical conditions.
Experiences with the complementary and alternative medicine (Ernst 2000)
market may be informative. Even for complementary medicine, where out-of-pocket
payments generated are measured in billions of dollars annually (Dodds et al. 2014;
Harris et al. 2012; Xue et al. 2007), no satisfactory mechanism ensures that adequate
efficiency and safety evidence is made available to consumers (Harvey 2012). Instead,
patients often rely on anecdotes provided by laypeople, peers, or relatives or acquired
over the Internet in deciding to try a health-related solution, despite the fact that
these stories do not represent reliable evidence and the solution has not been
endorsed by any expert authority (Harvey 2012; Williamson et al. 2008). The safety
problem is perhaps even more complex regarding solutions developed for personal
use by patients which, if they diffuse at all, usually spread for free through informal
peer-to-peer networks. The existing literature and practices do not offer reliable
answers to the question of how to validate the safety and efficacy of patient-devel-
oped solutions.
In light of this situation, we hope to extend the role of the Patient Innovation
community to include both the roles of innovator and tester of the self-developed
innovations. We are exploring innovative ways of collecting safety and efficacy data
that might create new opportunities for validating new treatments, therapies, or
medical devices.We are currently considering two possible approaches: the idea of a
“toolkit” for patient self-management of chronic medical conditions and the poten-
tial to implement observational trials of innovative treatments using our platform.
User innovation toolkits are integrated sets of specialized tools that enable end
users of a product or service to develop or modify products for themselves (von
Hippel 2005). Shifting a problem-solving task to users via a toolkit lowers costs when
users possess the information required to solve the problem in raw form and when it
is less expensive to transfer the tools needed to process that information to the user
than it is to transfer the user’s information to an expert.
This same economic logic may apply to medical toolkits devised for specific
purposes. Here we consider the possibility of toolkits for patient self-management
of chronic medical conditions. Such toolkits would offer patients the tools needed to
process their personal “raw” disease-related data into information that helps them
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manage their illnesses. The toolkit would give patients the information needed to (1)
appropriately recognize when to apply a prescribed or over-the-counter medical
treatment, (2) apply the treatment, (3) receive feedback on the results of the treat-
ment, and (4) make appropriate treatment adjustments without the involvement of a
health care specialist (DeMonaco et al. 2006). We are currently working on devel-
oping toolkits for allowing patients of some selected chronic diseases to test their self-
developed treatments, therapies, or medical devices. Such toolkits, interfacing with
the Patient Innovation platform, might help overcome the difficulties faced by
clinical trials of rare disease treatments: the need to “recruit” patients spread across
different areas and follow them for a longer period than typically needed for clinical
trials aimed at more common diseases. To enable better collection of data, we aim to
attract developers of cross-platform (Android, iOS, Windows) mobile applications,
which would be integrated with the Patient Innovation solution-sharing platform,
for patients to record vital health indicators and associate the recordings with the
solutions shared in the platform. Shifting the validation of user-developed treat-
ments, therapies, or medical devices to patients spread across different areas, using a
toolkit for data collection, would significantly lower the costs of generating data on
the safety and efficacy of the innovation.
Simply by providing an infrastructure for reporting patient innovations and
centralizing information about patient innovations in an easily accessible location,
Patient Innovation lowers barriers to the diffusion of innovation. The Patient
Innovation platform also lowers the barriers to diffusion because it facilitates the
patient-initiated search for solutions. Health needs often are heterogeneous, even
among different patients suffering from the same disease. Patients and caregivers
know their circumstances and needs better than anyone else and are well aware of
when their needs are addressed by conventional health care and health systems and
when they must adopt or discover solutions to fill in the gaps. By using an open
platform, Patient Innovation helps diffuse solutions proposed by patients and care-
givers, after careful screening for compliance with our terms of service. We are
currently exploring ways to develop an ecosystem, which would enable even wider
diffusion of solutions that have been proven to be of clinical efficacy.
conclusions
The global sharing of innovative solutions and treatments developed by patients and
their caregivers can potentially be a “game changer” in the health industry. The
innovation efforts by patients and their valuable solutions can potentially save
significant resources, reduce costs, promote the exchange of knowledge among
target stakeholders, and ultimately have an important social and economic impact.
Recognition of patient innovation also has the potential to enable patients to assume
more responsibility for the collaborative development and diffusion of medical
innovations. We have approached patient innovation along two complementary
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paths: an interdisciplinary scholarly research effort aimed at understanding the
patient innovation phenomenon and the design and launch of the Patient
Innovation online platform to encourage and facilitate the development and diffu-
sion of patient innovations. Our academic research helped frame the development
of the Patient Innovation platform. Implementing the platform has raised new
research questions in turn.
Feedback between scholarly research and practical application in the patient
innovation arena has the potential to produce great societal benefit. Consider how a
similar virtuous cycle has operated in the recently developed field of “entrepreneur-
ship.” Individuals have always created new firms. However, only recently have
researchers started studying entrepreneurship and firm creation in a systematic
way. The topic has become so popular that schools now offer courses on the topic.
The “buzz” has motivated people to become entrepreneurs, while the improved
understanding of entrepreneurship can be employed to empower them to do so.
Something similar can perhaps happen with patient innovation. With technology
and guidance, we can empower patients to innovate, and this is Patient Innovation’s
mission.
We have shown that patients are innovators, and we have developed the basic
infrastructure for a patient innovation knowledge commons, but much remains to
be done.Many patients do not even understand that they have the potential to create
valuable innovations – even if they are already doing so. Greater awareness of the
potential for patient innovation might motivate patients who have various poten-
tially relevant skills to become deeply involved in using those skills to improve their
health care – just as Tal Golesworthy employed his engineering skills to design his
aortic root external support. Numerous interesting questions for researchers in many
disciplines remain. Our experience implementing the Patient Innovation platform
uncovered questions lacking clear-cut solutions concerning intellectual property,
legal responsibility, medical ethics, and the methodology for assessing safety and
efficacy, just to name a few. We are only at the beginning of understanding patient
innovation and realizing its potential to benefit society. We invite those with the
skills and will to join our efforts, helping us understand and enable patient innova-
tors and to level the field for meaningful patient participation at all levels of
integrated health care.
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